0
1
1
1
0
0
1
1
1
0
The Clinical Institute Withdrawal Assessment for Alcohol, revised (CIWA-Ar) is the most widely used standardized instrument for quantifying the severity of alcohol withdrawal syndrome and guiding symptom-triggered pharmacotherapy. Developed by Sullivan et al. in 1989, the CIWA-Ar has become the standard of care in emergency departments, inpatient medical units, and addiction treatment facilities worldwide.
Alcohol withdrawal syndrome (AWS) occurs when individuals with chronic, heavy alcohol use abruptly reduce or cease consumption. It results from CNS hyperexcitability due to sudden removal of alcohol's depressive effects on GABA receptors and unmasking of compensatory glutamate (NMDA) upregulation.
AWS follows a predictable progression: minor symptoms (tremor, anxiety, insomnia, nausea) at 6-24 hours; seizures at 12-48 hours; alcoholic hallucinosis at 12-48 hours; and delirium tremens (DTs), the most severe form, at 48-96 hours with 5-15% mortality without treatment.
The CIWA-Ar evaluates 10 clinical domains: nausea/vomiting, tremor, paroxysmal sweats, anxiety, agitation, tactile disturbances, auditory disturbances, visual disturbances, headache, and orientation. Nine domains score 0-7 and orientation scores 0-4, yielding a maximum of 67.
The CIWA-Ar enables symptom-triggered therapy (STT), where benzodiazepines are administered based on measured severity rather than fixed schedules. RCTs demonstrate STT results in less total medication use, shorter treatment duration, and comparable or fewer complications versus fixed-schedule dosing.
For proper scoring, each domain requires careful clinical assessment. Tremor is assessed with arms extended and fingers spread. Sweating is observed on forehead and palms. Sensory disturbances range from mild sensitivity to frank hallucinations. Orientation tests awareness of date, place, and person.
Assessment frequency is score-driven: less than 8 every 4-8 hours, 8-15 every 2-4 hours, above 15 every 1-2 hours. Scores above 20 indicate risk of seizures and DTs requiring aggressive pharmacotherapy and possible ICU care.
This calculator implements the complete 10-item CIWA-Ar scale, providing total score, severity classification, and evidence-based management recommendations.
Score 10 clinical domains: nine scored 0-7 (nausea, tremor, sweats, anxiety, agitation, tactile/auditory/visual disturbances, headache) and one scored 0-4 (orientation). Total: 0-67. Higher scores indicate more severe withdrawal.
0-8: Mild; monitor q4-8h. 9-15: Moderate; consider benzodiazepines; q2-4h. 16-20: Severe; treat with benzodiazepines; q1-2h. >20: Very severe; risk of DTs; intensive therapy.
Inputs
Results
CIWA-Ar 6: mild symptoms; supportive care.
Inputs
Results
CIWA-Ar 31: very severe; aggressive treatment needed.
A 10-item scoring tool quantifying alcohol withdrawal severity to guide symptom-triggered benzodiazepine therapy.
67 (nine items 0-7 = 63, plus orientation 0-4 = 4).
Administering benzodiazepines based on CIWA-Ar scores rather than fixed schedules, reducing total medication and treatment duration.
Most protocols initiate at CIWA-Ar scores of 8-10 or higher.
Score <8: q4-8h. 8-15: q2-4h. >15: q1-2h.
The most severe AWS form with confusion, hallucinations, autonomic instability, seizures. Occurs 48-96h post-cessation, 5-15% mortality untreated.
Higher scores correlate with increased risk. Scores above 15-20 warrant seizure precautions.
Trained nursing staff or physicians. Consistent training ensures accurate scoring.
Chlordiazepoxide, diazepam (long-acting), lorazepam (preferred in liver disease), oxazepam (short-acting).
No. CIWA-Ar is specifically for alcohol withdrawal. Different tools exist for benzodiazepine withdrawal.
Roboculator Team
The Roboculator Team explains calculations, planning tools, and practical formulas in clear language for real-life situations.
How helpful was this calculator?
Be the first to rate!